2021
Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Beckwith H, Schwab R, Yau C, Stringer-Reasor E, Wei S, Chien A, Albain K, Kalinsky K, Wallace A, Elias A, Yee D, Clark A, Boughey J, Han H, Nanda R, Isaacs C, Mitri Z, Lang J, Thomas A, Sanft T, DeMichele A, Perlmutter J, Rugo H, Hylton N, Symmans W, Melisko M, van't Veer L, Wilson A, Asare S, Sanil A, Berry D, Esserman L. Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2021, 81: pd1-10-pd1-10. DOI: 10.1158/1538-7445.sabcs20-pd1-10.Peer-Reviewed Original ResearchStage II/III breast cancerWeekly x 4I-SPY 2 TRIALI-SPY 2PCR rateBreast cancerI-SPYPeripheral neuropathyHigh-risk stage II/III breast cancerTumor samplesRates of peripheral neuropathyControl armEvaluate novel agentsPathological complete responsePhase 2 trialTreatment of angiosarcomaModerate to high expressionSide effect profileTime of surgeryBayesian predictive probability of successBreast tumor samplesAntibody drug conjugatesHR-HER2Complete responseNeoadjuvant therapy
2020
Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial
Li W, Onishi N, Newitt D, Gibbs J, Wilmes L, Jones E, Joe B, Sit L, Yau C, Chien A, Price E, Albain K, Kuritza T, Morley K, Boughey J, Brandt K, Choudhery S, Clark A, Rosen M, McDonald E, Elias A, Wolverton D, Fountain K, Euhus D, Han H, Niell B, Drukteinis J, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yee D, Yung R, Asare S, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Berry D, DeMichele A, Abe H, Sheth D, Edmiston K, Ellis E, Ha R, Wynn R, Crane E, Dillis C, Nelson M, Church A, Isaacs C, Khan Q, Oh K, Jafarian N, Bang D, Mullins C, Woodard S, Zamora K, Ojeda-Fornier H, Sheth P, Hovanessian-Larsen L, Eghtedari M, Spektor M, Giurescu M, Newell M, Cohen M, Berman E, Lehman C, Smith W, Fitzpatrick K, Borders M, Yang W, Dogan B, Goudreau S, Brown T, Esserman L, Hylton N. Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial. Cancer Research 2020, 80: pd9-04-pd9-04. DOI: 10.1158/1538-7445.sabcs19-pd9-04.Peer-Reviewed Original ResearchI-SPY 2 TRIALFunctional tumor volumeTumor volume progressionTumor progressionNon-pCRI-SPYTumor volumeHER2 subtypeVolume progressionCancer subtypesTumour progressorsEvaluate MRI changesI-SPY 2Triple negative subtypeHER2+ tumorsHigh-risk patientsNegative predictive valueBreast cancer subtypesEnhancement post-contrastTime pointsNumbers of patientsInsufficient image qualityTreatment time pointsPost-NACPre-NAC